COMPOSITION :
Ivermectin................................................ ...................1.00 g
Clorsulon….................................................. ................10.00 g
Excipient q.s.p................................................. ............ 100 ml
PHARMACEUTICAL PROPERTIES
Ivermectin is an antiparasitic of the avermectin family endowed with great activity on both internal and external parasites of domestic animals (endectocide). Ivermectin acts on nematodes and arthropods through gamma amino-butyric acid (GABA). It causes its release by the presynaptic membrane and potentiates its binding to receptors located on the post-synaptic membrane. GABA is a neuromediator involved in the transmission of inhibitory messages between the inter-neuron and the motor neuron in nematodes, and between the nerve fiber and the muscle cell in arthropods.
At recommended doses, ivermectin is very well tolerated in both adults and young people and can be used at all stages of gestation. Ivermectin is not active against flukes and tapeworms.
Clorsulone inhibits enzymes of the Fasciola hepatica glycolytic system (3- phosphoglycerate kinase and phosphoglyceromutase). This enzymatic inhibition blocks the Embden-Myerhof glycolytic pathway, the main energy source of Fasciola hepatica.
The combination of the two active ingredients makes it possible to further broaden the spectrum of the preparation.
TARGET SPECIES
Sheep, cattle
INDICATIONS
Treatment of gastrointestinal and pulmonary roundworms, trematodiases, external infestations due to lice and scabies agents, ovine oestrosis and bovine hypodermosis.
ADMINISTRATION AND DOSAGE
ATLAMEC-D is recommended exclusively by the subcutaneous route at a single dose of 1 ml of solution/50 kg of bodyweight, corresponding to 0.2 mg of ivermectin and 2 mg of clorsulon per kilogram of bodyweight.
CONTRAINDICATIONS AND INTERACTIONS
Do not use in dairy females when the milk or its derivatives are intended for human consumption.
None if all recommendations are followed.
SIDE EFFECTS
If the general terms of use are followed, no adverse effects are observed after treatment with Atlamec-D.
PRECAUTIONS FOR USE
- Do not inject intravenously or intramuscularly.
- Do not smoke or eat while using the product.
- Do not leave within reach of children.
- Avoid contact with skin or eyes.
- Destroy the bottle after use.
WITHDRAWAL PERIOD
Meat and offal: 28 days
Milk: Do not use in dairy females when the milk or its derivatives are intended for human consumption.
STORAGE CONDITIONS
Product stable for 2 years in the original packaging, protected from light and at a temperature < 25°C.
Stability after opening: 4 weeks
PHARMACEUTICAL FORM AND PRESENTATION:
Bottle of 50 and 100 ml